Alemtuzumab in refractory Sézary syndrome

Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promis...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:An Bras Dermatol
Autori principali: Reifs, Carmen María Alcántara, Salido-Vallejo, Rafael, Garnacho-Saucedo, Gloria María, la Corte-Sánchez, Sofía De, González-Menchen, Alberto, García-Nieto, Antonio Vélez
Natura: Artigo
Lingua:Inglês
Pubblicazione: Sociedade Brasileira de Dermatologia 2016
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087225/
https://ncbi.nlm.nih.gov/pubmed/27828640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/abd1806-4841.20164322
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi